Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04276259 · ClinicalTrials.gov registry record · Phase 4
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
A Phase 4 study, sponsored by Marta Peciña, MD PhD.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT04276259 is a Phase 4 study that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 120 participants.
The verdict
NCT04276259, a Phase 4 study, has completed, sponsored by Marta Peciña, MD PhD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC (Aim 2) and μ-opioid striatal RPE signal using pharmacological approaches (Aim 3).
Interventions
- DRUG Oral Placebo
- DRUG Buprenorphine
- DRUG Naltrexone
- DRUG IM Placebo
- DEVICE Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04276259
The ClinicalTrials.gov registry entry for NCT04276259 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marta Peciña, MD PhD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT04276259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04276259 about?
NCT04276259 is a clinical study titled "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses". The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting t...
What is the current status of trial NCT04276259?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2020-10-19. Estimated completion is 2026-03-31.
What interventions are being tested in trial NCT04276259?
The interventions under investigation include: Oral Placebo (DRUG), Buprenorphine (DRUG), Naltrexone (DRUG), IM Placebo (DRUG), Theta burst stimulation (TBS) of the ventromedial prefrontal cortex. (DEVICE).
Who is sponsoring clinical trial NCT04276259?
This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.